All patients
subjects at risk
chloroquine and derivatives in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 0.69 [0.28; 1.68]
RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
1.10 [0.98 ; 1.22 ] FACCT Trial, 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 3 0% 6,823 moderate not evaluable deathsdetailed results Abd-Elsalam, 2020 1.21 [0.36; 4.12]
ARCHAIC -hydroxychloroquine, 2020 5.00 [0.13; 185.58]
CCAP-1, 2020 1.00 [0.00; 255.63]
Chen, 2020 0.56 [0.01; 30.20]
Chen, ChiCTR2000030054 - Chloroquine, 2020 0.66 [0.01; 35.52]
ChiCTR2000030054-HCQ (Chen), 2020 0.66 [0.01; 35.52]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
Duke university HCQ, 2020 1.00 [0.02; 50.40]
Duke University hydroxychloroquine/azithromycine, 2020 0.50 [0.01; 19.56]
FACCT Trial, 2021 0.96 [0.44; 2.08]
HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89]
NCT04333654, 2020 0.56 [0.01; 37.57]
NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
OAHU-COVID19, 2020 2.75 [0.10; 73.35]
PROTECT A, 2020 0.50 [0.02; 15.30]
PROTECT B, 2020 0.51 [0.04; 6.12]
RECOVERY, 2020 1.09 [0.97; 1.23]
REMAP-CAP-HCQ, 2020 1.04 [0.49; 2.19]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Tang, 2020 1.00 [0.02; 51.07]
1.10 [0.99 ; 1.23 ] Abd-Elsalam, 2020, ARCHAIC -hydroxychloroquine, 2020, CCAP-1, 2020, Chen, 2020, Chen, ChiCTR2000030054 - Chloroquine, 2020, ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, Duke university HCQ, 2020, Duke University hydroxychloroquine/azithromycine, 2020, FACCT Trial, 2021, HC-nCoV (Shanghai), 2020, NCT04333654, 2020, NO COVID-19 (Lyngbakken), 2020, NOR-Solidarity (hydroxychloroquine), 2021, OAHU-COVID19, 2020, PROTECT A, 2020, PROTECT B, 2020, RECOVERY, 2020, REMAP-CAP-HCQ, 2020, SOLIDARITY (WHO study) HCQ, 2020, Tang, 2020 21 0% 8,218 moderate low deaths (time to event analysis only)detailed results NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
1.11 [0.99 ; 1.23 ] NOR-Solidarity (hydroxychloroquine), 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 3 0% 6,681 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
Kamran, 2020 0.95 [0.32; 2.78]
Zhaowei Chen, 2020 0.11 [0.01; 2.19]
1.02 [0.54 ; 1.93 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, Kamran, 2020, Zhaowei Chen, 2020 3 18% 894 moderate not evaluable clinical improvementdetailed results Tang, 2020 1.01 [0.59; 1.74]
1.01 [0.59 ; 1.74 ] Tang, 2020 1 0% 119 NA not evaluable clinical improvement (14-day)detailed results Chen, 2020 0.56 [0.13; 2.48]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
0.79 [0.47 ; 1.33 ] Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 2 0% 481 moderate not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 0.85 [0.62; 1.16]
Tang, 2020 1.01 [0.59; 1.74]
0.88 [0.67 ; 1.16 ] FACCT Trial, 2021, Tang, 2020 2 0% 373 moderate not evaluable death or ventilationdetailed results RECOVERY, 2020 1.14 [1.03; 1.27]
SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42]
1.14 [1.03 ; 1.25 ] RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 2 0% 5,776 moderate not evaluable hospital dischargedetailed results FACCT Trial, 2021 0.88 [0.64; 1.21]
0.88 [0.64 ; 1.21 ] FACCT Trial, 2021 1 0% 254 NA not evaluable radiologic improvement (7-day)detailed results Zhaowei Chen, 2020 3.43 [1.10; 10.70]
3.43 [1.10 ; 10.70 ] Zhaowei Chen, 2020 1 0% 62 NA not evaluable viral clearance detailed results HC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75]
Tang, 2020 0.85 [0.58; 1.23]
0.83 [0.57 ; 1.21 ] HC-nCoV (Shanghai), 2020, Tang, 2020 2 0% 180 serious not evaluable viral clearance (time to event analysis only)detailed results Tang, 2020 0.85 [0.58; 1.23]
0.85 [0.58 ; 1.23 ] Tang, 2020 1 0% 150 NA not evaluable viral clearance by day 14detailed results Chen, 2020 1.42 [0.26; 7.76]
1.42 [0.26 ; 7.76 ] Chen, 2020 1 0% 33 NA not evaluable ICU admissiondetailed results Abd-Elsalam, 2020 0.83 [0.35; 1.95]
FACCT Trial, 2021 1.42 [0.79; 2.55]
1.19 [0.72 ; 1.96 ] Abd-Elsalam, 2020, FACCT Trial, 2021 2 4% 448 moderate not evaluable cardiac arrestdetailed results SOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49]
1.92 [0.35 ; 10.49 ] SOLIDARITY (WHO study) HCQ, 2020 1 0% 1,853 NA not evaluable adverse eventsdetailed results Chen, ChiCTR2000030054 - Chloroquine, 2020 4.00 [0.67; 23.73]
ChiCTR2000030054-HCQ (Chen), 2020 5.00 [0.85; 29.57]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01]
RECOVERY, 2020 1.36 [0.98; 1.90]
Tang, 2020 4.47 [1.77; 11.31]
1.99 [1.10 ; 3.61 ] Chen, ChiCTR2000030054 - Chloroquine, 2020, ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HC-nCoV (Shanghai), 2020, RECOVERY, 2020, Tang, 2020 6 46% 5,288 moderate not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-05 15:12 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 508,656,657,832
- roots T: 290
